A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers

Subotheni Thavaneswaran; Frank P Lin; Maya Kansara; John P Grady; David Espinoza; Anthony M Joshua; Peter Grimison; Paul Craft; Rasha Cosman; Chee Lee; Kathleen Harwood; Sarah Chinchen; Theresa Corpuz; Mandy Ballinger; Lucille Sebastian; John Simes; David Thomas

doi:10.1101/2022.06.30.22277092

A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers

View ORCID ProfileSubotheni Thavaneswaran, View ORCID ProfileFrank P Lin, Maya Kansara, John P Grady, David Espinoza, Anthony M Joshua, Peter Grimison, Paul Craft, Rasha Cosman, Chee Lee, Kathleen Harwood, Sarah Chinchen, Theresa Corpuz, Mandy Ballinger, Lucille Sebastian, John Simes, David Thomas

doi: https://doi.org/10.1101/2022.06.30.22277092

Subotheni Thavaneswaran

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Subotheni Thavaneswaran
For correspondence: s.thavaneswaran@garvan.org.au

Frank P Lin

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

4Kinghorn Centre for Clinical Genomics, Garvan Institute of Medical Research, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site
ORCID record for Frank P Lin

Maya Kansara

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John P Grady

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David Espinoza

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Anthony M Joshua

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Peter Grimison

5Chris O’Brien Lifehouse, Camperdown, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Paul Craft

6The Canberra Hospital, ANU Medical School. Canberra, ACT, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Rasha Cosman

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Chee Lee

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Kathleen Harwood

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Sarah Chinchen

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Theresa Corpuz

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Mandy Ballinger

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Lucille Sebastian

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

John Simes

2NHMRC Clinical Trials Centre, University of Sydney, Sydney, NSW, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

David Thomas

1The Kinghorn Cancer Centre, Garvan Institute of Medical Research, Sydney, NSW, Australia

3School of Clinical Medicine, Faculty of Medicine and Health, UNSW Sydney, Australia

Find this author on Google Scholar
Find this author on PubMed
Search for this author on this site

Abstract
Full Text
Info/History
Metrics
Supplementary material
Data/Code
Preview PDF

Data Availability

All data produced in the present study are available upon reasonable request to the authors.

View the discussion thread.

PreviousNext

Posted July 03, 2022.

Download PDF

Supplementary Material

Data/Code

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Your Email *

Your Name *

Send To *

Enter multiple addresses on separate lines or separate them with commas.

You are going to email the following A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers

Message Subject (Your Name) has forwarded a page to you from medRxiv

Message Body (Your Name) thought you would like to see this page from the medRxiv website.

Your Personal Message

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

A signal-seeking Phase II trial of Durvalumab and Tremelimumab Focused on Advanced, Rare and Less Common Cancers

Subotheni Thavaneswaran, Frank P Lin, Maya Kansara, John P Grady, David Espinoza, Anthony M Joshua, Peter Grimison, Paul Craft, Rasha Cosman, Chee Lee, Kathleen Harwood, Sarah Chinchen, Theresa Corpuz, Mandy Ballinger, Lucille Sebastian, John Simes, David Thomas

medRxiv 2022.06.30.22277092; doi: https://doi.org/10.1101/2022.06.30.22277092

Share This Article: